SEC Form 4 · accession 0001159036-26-000108
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — PRESIDENT AND CEO · Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 19, 2026 · 8:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2026 | M | 20,000 | $18.41 | A | 787,780 | D | |
| Common StockF2 | Aug 17, 2026 | S | 900 | $98.958 | D | 786,880 | D | |
| Common StockF3 | Aug 17, 2026 | S | 500 | $100.457 | D | 786,380 | D | |
| Common StockF4 | Aug 17, 2026 | S | 2,100 | $101.766 | D | 784,280 | D | |
| Common StockF5 | Aug 17, 2026 | S | 9,000 | $102.553 | D | 775,280 | D | |
| Common StockF6 | Aug 17, 2026 | S | 7,500 | $103.482 | D | 767,780 | D | |
| Common Stock | Aug 18, 2026 | M | 20,000 | $18.41 | A | 787,780 | D | |
| Common StockF7 | Aug 18, 2026 | S | 5,703 | $103.083 | D | 782,077 | D | |
| Common StockF8 | Aug 18, 2026 | S | 4,897 | $104.11 | D | 777,180 | D | |
| Common StockF9 | Aug 18, 2026 | S | 9,400 | $104.874 | D | 767,780 | D | |
| Common Stock | Aug 19, 2026 | M | 20,000 | $18.41 | A | 787,780 | D | |
| Common StockF10 | Aug 19, 2026 | S | 7,200 | $106.358 | D | 780,580 | D | |
| Common StockF11 | Aug 19, 2026 | S | 9,600 | $107.224 | D | 770,980 | D | |
| Common StockF12 | Aug 19, 2026 | S | 3,200 | $107.765 | D | 767,780 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF13 | $18.41 | Aug 17, 2026 | M | 20,000 | D | — | Feb 14, 2028 | Common Stock | 20,000 | 181,552 | D |
| Option to Purchase Common StockF13 | $18.41 | Aug 18, 2026 | M | 20,000 | D | — | Feb 14, 2028 | Common Stock | 20,000 | 161,552 | D |
| Option to Purchase Common StockF13 | $18.41 | Aug 19, 2026 | M | 20,000 | D | — | Feb 14, 2028 | Common Stock | 20,000 | 141,552 | D |
Explanation of responses
- F1The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
- F10Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F11Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F12Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F13Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
- F2Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.